<DOC>
	<DOCNO>NCT00170846</DOCNO>
	<brief_summary>The study design evaluate whether initiation everolimus together reduction discontinuation calcineurin inhibitor ( CNIs ) improve graft function maintenance renal transplant recipient renal impairment reduce progression chronic allograft nephropathy . The development atherosclerosis native artery patient also explore .</brief_summary>
	<brief_title>ASCERTAIN : Assessment Everolimus Addition Calcineurin Inhibitor Reduction Maintenance Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Male female patient least 18 year age . Patient undergone primary secondary renal transplant 1296 month ago living relate unrelated donor cadaveric donor . Patient receive cyclosporine microemulsion C2h level ≥ 400 ng/mL tacrolimus C0h level ≥ 4 ng/mL without mycophenolic acid azathioprine plus minus steroid . The immunosuppressive regimen must remain unchanged within last 3 month . Patient renal impairment define GFR 30 70 mL/min/1.73 m^2 CockcroftGault formula . Patient recipient multiple organ transplant . Patient protein/creatinine ratio ≥ 150 ( mg/mmol ) . Patient treat acute rejection episode within last 3 month . Patient past present BKpolyomavirus nephropathy . Patient de novo recurrent glomerular nephritis . Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Renal transplantation , everolimus , calcineurin inhibitor , GFR</keyword>
</DOC>